One limitation is that we have not yet explored the optimal therapeutic dose of EU-Idd for rheumatoid arthritis, and another limitation is that our results have not been verified by using JAK2/STAT3 pathway inhibitor. This evidence concerns the gene JAK2 and rheumatoid arthritis.